

Disclaimer

Earnings forecasts are produced by the contributing registered investment analysts currently covering RB.

The estimates that are used to compile the consensus are the sole responsibility of the registered investment analysts. RB uses Vuma to compile the consensus information, and does not endorse or concur with such analyst information, conclusions or recommendations. RB has not verified any of the information received and none of RB, its affiliates or any of its or their respective directors, officers and employees make any representation or warranty, express or implied, as to, or accepts any responsibility for, the accuracy or completeness of the consensus information. RB shall not be liable (whether in contract, tort or otherwise) for any errors, inaccuracies or omissions in

the content of the information (either at the date of issue of these forecasts, or any other date), or for any action taken in reliance thereon. RB does not assume any responsibility to update, revise or supplement such information.

The information provided by RB is for information purposes only and is not intended for trading purposes. It should be noted that forecasts are forward-looking and are therefore subject to risks and uncertainties (including unknown risks and uncertainties) that may materially affect eventual results.

THE FORECASTS PROVIDED ARE BASED ON A MEAN AVERAGE OF ESTIMATES PROVIDED AND DO NOT REPRESENT OR REFLECT, AND SHOULD NOT BE DEEMED TO BE, RB'S OPINIONS, ESTIMATES OR FORECASTS.

	Q1 FY20	Q1 FY20	Q1 FY20	FY20	FY20	FY20	FY21	FY21	FY21	FY22	FY22	FY22
	CONSENSUS	MIN	MAX	CONSENSUS	MIN	MAX	CONSENSUS	MIN	MAX	CONSENSUS	MIN	MAX
kitt Benckiser Group Plc												
t Revenue Growth: Like for Like %												
CN	0.8	-6.8	9.0	0.8	-2.4	3.7	2.7	1.5	4.7	3.5	2.0	4.0
TC	9.9	3.0	28.0	5.6	0.4	13.3	2.2	-3.0	5.0	4.1	2.5	6.0
ther	7.4	-0.6	35.0	3.5	-1.5	8.0	2.3	-0.1	4.0	3.8	-0.3	5.
al Health	5.5	0.0	20.2	3.0	0.6	6.3	2.5	1.2	3.9	3.9	2.1	5
giene Home	5.1	2.0	8.0	3.8	1.0	7.5	2.5	1.0	3.4	3.4	2.5	4.4
oup growth: like-for-like %	5.3	1.2	13.9	3.3	1.5	5.2	2.5	1.1	3.6	3.7	2.4	4.4
t M&A impact %	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0
impact %	-1.0	-3.2	3.6	-1.4	-4.6	3.1	-0.1	-0.9	1.0	-0.2	-0.9	0.
oup growth: NR growth (Actual rates) - continuing operations %	4.3	-2.1	11.9	1.9	-1.9	8.1	2.4	0.3	3.6	3.5	1.5	4.:
: Revenue - Total Reported £												
N	760	676	837	2,983	2,786	3,241	3,062	2,796	3,312	3,163	2,894	3,41
OTC	510	479	592	2,019	1,857	2,154	2,065	1,880	2,192	2,148	1,945	2,31
Other	753	706	939	2,948	2,739	3,197	3,017	2,770	3,293	3,136	2,865	3,45
al Health	2,023	1,869	2,290	7,950	7,571	8,407	8,144	7,671	8,676	8,447	7,970	9,07
iene Home	1,271	1,222	1,357	5,140	4,986	5,486	5,265	5,092	5,651	5,435	5,220	5,84
I Net Revenue	3,294	3,091	3,531	13,090	12,597	13,894	13,408	12,863	14,327	13,882	13,307	14,92
ating Profit - Adjusted												
alth				1,763	1,643	1,928	1,829	1,678	1,969	2,004	1,851	2,15
iene Home	_			1,227	1,134	1,332	1,267	1,188	1,338	1,334	1,242	1,43
Operating Profit - Adjusted				2,990	2,862	3,153	3,096	2,923	3,258	3,337	3,167	3,54
rating Margin % - Adjusted alth				22.2	20.9	23.7	22.5	20.8	23.7	23.7	22.1	25
giene Home				22.2	20.9 21.5	23.7	22.5	20.8	23.7	23.7	22.1 23.4	25
al Operating Margin % - Adjusted				23.5	21.5	23.5	23.1	22.4	23.6	24.0	23.4	25.
Finance Evenese Adjusted				202	222	242	270	220	222	252	225	10
Finance Expense - Adjusted				-293	-327	-243	-276	-328	-222	-252	-325	-19 -65
on (expense)/benefit - Adjusted				-615 -14	-659 -25	-573 -10	-644 -14	-690 -25	-591 -8	-704 -15	-763 -26	-05
ontrolling Interest				-14	-25	-10	-14	-25	-0	-15	-20	-
nuing Operations				2.067	1.000	2 102	2.462	2 0 2 0	2 200	2.200	2 4 7 4	2 5 4
income - adjusted				2,067	1,966	2,192	2,162	2,028	2,298	2,366	2,174	2,54
erage number of shares on a diluted basis				710.1	708.7	717.7	711.0	708.7	723.2	711.1	693.2	728.
5, Group, fully diluted, adjusted (p)				291.1	277.3	309.3	304.1	286.0	322.9	332.7	313.6	355